Home » Stocks » KALA

Kala Pharmaceuticals, Inc. (KALA)

Stock Price: $7.46 USD -0.09 (-1.19%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
After-hours: $7.77 +0.31 (4.16%) Jan 21, 7:47 PM
Market Cap 415.52M
Revenue (ttm) 5.30M
Net Income (ttm) -95.17M
Shares Out 56.03M
EPS (ttm) -2.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $7.46
Previous Close $7.55
Change ($) -0.09
Change (%) -1.19%
Day's Open 7.52
Day's Range 7.37 - 7.54
Day's Volume 1,770,343
52-Week Range 5.35 - 13.79

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 day ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside ...

Business Wire - 2 weeks ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies fo...

Business Wire - 2 weeks ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for...

Seeking Alpha - 4 weeks ago

Kala Pharmaceuticals Should Have Limited Downside With Eysuvis Now Approved

Business Wire - 1 month ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside ...

Seeking Alpha - 1 month ago

The Play On Kala Pharmaceuticals

Business Wire - 2 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside ...

Business Wire - 2 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies fo...

Business Wire - 2 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for...

Seeking Alpha - 2 months ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Kala Pharma (KALA) delivered earnings and revenue surprises of -13.64% and 9.74%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 2 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for...

Business Wire - 2 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for...

The Motley Fool - 2 months ago

Good news from the FDA translated to bad news for Kala's share price.

Business Wire - 2 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for...

Zacks Investment Research - 3 months ago

Investors need to pay close attention to Kala Pharmaceuticals (KALA) stock based on the movements in the options market lately.

Zacks Investment Research - 3 months ago

Kala Pharmaceuticals (KALA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Business Wire - 4 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc.

Business Wire - 4 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc.

Seeking Alpha - 5 months ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Kala Pharma (KALA) delivered earnings and revenue surprises of 0.00% and 9.89%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 5 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc.

Business Wire - 5 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc.

Business Wire - 5 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc.

Zacks Investment Research - 5 months ago

Kala Pharma (KALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 7 months ago

Is (KALA) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 7 months ago

Top Ranked Momentum Stocks to Buy for May 26th

Other stocks mentioned: KOPN, NERV, RYAM
Zacks Investment Research - 8 months ago

Is (KALA) Outperforming Other Medical Stocks This Year?

Seeking Alpha - 8 months ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Kala Pharma (KALA) delivered earnings and revenue surprises of -5.88% and -57.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 8 months ago

Shares of Kala Pharmaceuticals (NASDAQ:KALA) were flat in pre-market trading after the company reported Q1 results.

Zacks Investment Research - 8 months ago

Does Kala Pharmaceuticals (KALA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor in Kala Pharmaceuticals.

Zacks Investment Research - 9 months ago

Does Kala Pharmaceuticals (KALA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 9 months ago

Coronavirus shows signs of slowdown in the United States and some other countries. While investors look for positive developments in the stock market, here are five must-buy stocks poised to g...

Other stocks mentioned: DHT, FRO, SMED, SMMT
Zacks Investment Research - 9 months ago

Picking breakout stocks is one of the most favored methods for those utilizing an active investing approach since this strategy offers the promise of superlative returns.

Other stocks mentioned: CCOEY, UNICY
Seeking Alpha - 9 months ago

Kala Pharmaceuticals Looks To Keep Rally Going

Seeking Alpha - 9 months ago

Kala Pharmaceuticals achieved positive results from its phase 3 STRIDE-3 study using EYSUVIS to treat patients with dry eye disease.

Zacks Investment Research - 10 months ago

Is (KALA) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 10 months ago

As of late, it has definitely been a great time to be an investor in Kala Pharmaceuticals, Inc. (KALA).

Zacks Investment Research - 10 months ago

Top Ranked Momentum Stocks to Buy for March 10th

Other stocks mentioned: CODX, HMY, SSTI
Zacks Investment Research - 10 months ago

Investors need to pay close attention to Kala Pharmaceuticals (KALA) stock based on the movements in the options market lately.

Seeking Alpha - 11 months ago

Kala Pharmaceuticals: Solid Progress

Seeking Alpha - 11 months ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

Kala Pharma (KALA) delivered earnings and revenue surprises of -5.00% and -59.56%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 1 year ago

If STRIDE 3 trial succeeds, it would open an additional large target market in dry eye disease. An estimate of its pipeline value is provided.

Seeking Alpha - 1 year ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Kala Pharma (KALA) delivered earnings and revenue surprises of -1.49% and -59.20%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 1 year ago

Kala Pharmaceuticals had received a CRL for its corticosteroid drug known as KPI-121 0.25% for the treatment of dry eye disease.

The Motley Fool - 1 year ago

The growing eye industry is something investors can’t ignore.

Other stocks mentioned: EYPT, NVS, OCUL

About KALA

Kala Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; ... [Read more...]

Industry
Biotechnology
IPO Date
Jul 20, 2017
CEO
Mark Iwicki
Employees
136
Stock Exchange
NASDAQ
Ticker Symbol
KALA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for KALA stock is "Buy." The 12-month stock price forecast is 21.50, which is an increase of 188.20% from the latest price.

Price Target
$21.50
(188.20% upside)
Analyst Consensus: Buy